Cystitis, Interstitial Clinical Trial
Official title:
Efficacy of DMSO Cocktail Treatment in Interstitial Cystitis Patients During and After Treatment
The purpose of this study is to examine the efficacy of dimethylsulphoxide (DMSO) cocktail in patients with interstitial cystitis during the treatment period (12 weeks) and after it (at 6 weeks, 3, 6 and 12 month).
The modern treatment of IC is a multi-modal treatment which includes behavioural treatment,
physiotherapy of the pelvic floor musculature, oral medication (e.g. Amitryptiline) and
intra-vesical instillation (e.g. DMSO, steroids, heparin). These treatments were found to be
effective in a number of studies and are approved by the FDA. However, the optimal duration
of intra-vesical instilation is not known.
All patients with IC (according to the international continence society criteria) will
receive 12 weekly intra-vesical instillation of DMSO. All patients will fill an O'leary-Sant
questionaire and a urination diary before treatment, after 3, 6, 9 and 12 treatments and at
6 weeks, 3, 6 and 12 month after the end to the treatment.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02868775 -
A Study to Determine the Role of Toll-like Receptor-4 Expression in Patients With Interstitial Cystitis/Bladder Pain Syndrome
|
N/A | |
Completed |
NCT00672087 -
Diagnostic Challenges in IC (and Male CPPS)
|
||
Completed |
NCT01482676 -
The Role of microRNAs in Organ Remodeling in Lower Urinary Tract Dysfunction
|
N/A | |
Terminated |
NCT00380783 -
Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis
|
Phase 2 | |
Completed |
NCT00775281 -
Changes in Inflammatory and Contractile Protein Expression in Patients With Painful Bladder Syndrome/IC.
|
N/A | |
Completed |
NCT05260112 -
Smartphone-based Self-care Education Program for Women With Interstitial Cystitis: Educational Remote IC Aide
|
N/A | |
Completed |
NCT05752344 -
Interstitial Cystitis: Monitoring of the Psychic State and Counseling Intervention in the COVID-19 Era
|
||
Completed |
NCT01613586 -
A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC)
|
Phase 2 | |
Completed |
NCT02411110 -
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome
|
Phase 2 | |
Recruiting |
NCT06299683 -
Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment
|
N/A | |
Completed |
NCT00248664 -
Events Preceding Interstitial Cystitis (EPIC)
|
N/A | |
Completed |
NCT00601484 -
An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis
|
Phase 2 | |
Completed |
NCT02214550 -
Chronic Pain Risk Associated With Menstrual Period Pain
|
Phase 4 | |
Completed |
NCT04275297 -
Optimizing Psychosocial Treatment of Interstitial Cystitis/Bladder Pain Syndrome
|
N/A | |
Terminated |
NCT00999518 -
A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome
|
Phase 2 | |
Completed |
NCT00675298 -
Linkage Analysis in Interstitial Cystitis
|
N/A | |
Terminated |
NCT02781103 -
Guided Imagery and Transcranial Direct Current Stimulation (tDCS) in Women With Chronic Pelvic Pain
|
N/A | |
Completed |
NCT02497976 -
Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis
|
Phase 3 | |
Terminated |
NCT02787083 -
A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis
|
Phase 3 | |
Withdrawn |
NCT00275379 -
Study Evaluating Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis
|
N/A |